Stockholder Equity (Details 3) |
3 Months Ended |
|---|---|
|
Mar. 31, 2026
$ / shares
shares
| |
| Nonvested,end of the period | 174,767 |
| Unvested time-based RSUs [Member] | |
| Nonvested, beginning of the period | 593,487 |
| Vested | (166,221) |
| Forfeited | (153,545) |
| Nonvested,end of the period | 273,721 |
| Weighted Average Exercise Price, beginning balance | $ / shares | $ 5.02 |
| Weighted Average Exercise Price vested | $ / shares | 5.45 |
| Weighted Average Exercise Price forfeited | $ / shares | 5.35 |
| Weighted Average Exercise Price, ending balance | $ / shares | $ 4.58 |
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options forfeited. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of non-vested options outstanding. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition Weighted average grant-date fair value of options vested. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|